Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 83

Similar articles for PubMed (Select 23576735)

1.

Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer.

Magnani L, Stoeck A, Zhang X, Lánczky A, Mirabella AC, Wang TL, Gyorffy B, Lupien M.

Proc Natl Acad Sci U S A. 2013 Apr 16;110(16):E1490-9. doi: 10.1073/pnas.1219992110. Epub 2013 Apr 1.

2.

Chromatin landscape and endocrine response in breast cancer.

Magnani L, Brunelle M, Gévry N, Lupien M.

Epigenomics. 2012 Dec;4(6):675-83. doi: 10.2217/epi.12.64. Review.

PMID:
23244312
3.

Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.

Kuske B, Naughton C, Moore K, Macleod KG, Miller WR, Clarke R, Langdon SP, Cameron DA.

Endocr Relat Cancer. 2006 Dec;13(4):1121-33.

4.

Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.

Chang HL, Sugimoto Y, Liu S, Ye W, Wang LS, Huang YW, Lin YC.

Anticancer Res. 2006 May-Jun;26(3A):1773-84.

5.

PBX1 genomic pioneer function drives ERα signaling underlying progression in breast cancer.

Magnani L, Ballantyne EB, Zhang X, Lupien M.

PLoS Genet. 2011 Nov;7(11):e1002368. doi: 10.1371/journal.pgen.1002368. Epub 2011 Nov 17.

6.

Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor.

Masri S, Phung S, Wang X, Wu X, Yuan YC, Wagman L, Chen S.

Cancer Res. 2008 Jun 15;68(12):4910-8. doi: 10.1158/0008-5472.CAN-08-0303.

7.

Prognosis of hormone-dependent breast cancers: implications of the presence of dysfunctional transcriptional networks activated by insulin via the immune transcription factor T-bet.

McCune K, Bhat-Nakshatri P, Thorat MA, Nephew KP, Badve S, Nakshatri H.

Cancer Res. 2010 Jan 15;70(2):685-96. doi: 10.1158/0008-5472.CAN-09-1530. Epub 2010 Jan 12.

8.

Epigenetic reprogramming of breast cancer cells by valproic acid occurs regardless of estrogen receptor status.

Travaglini L, Vian L, Billi M, Grignani F, Nervi C.

Int J Biochem Cell Biol. 2009 Jan;41(1):225-34. doi: 10.1016/j.biocel.2008.08.019. Epub 2008 Aug 22.

PMID:
18789398
9.

Cellular reprogramming by the conjoint action of ERα, FOXA1, and GATA3 to a ligand-inducible growth state.

Kong SL, Li G, Loh SL, Sung WK, Liu ET.

Mol Syst Biol. 2011 Aug 30;7:526. doi: 10.1038/msb.2011.59.

10.

Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.

Imachi H, Murao K, Dobashi H, Bhuyan MM, Cao X, Kontani K, Niki S, Murazawa C, Nakajima H, Kohno N, Yamashita H, Iwase H, Hayashi S, Ishida T, Yamauchi A.

Breast Cancer Res Treat. 2010 Jul;122(2):395-407. doi: 10.1007/s10549-009-0581-0. Epub 2009 Oct 22.

PMID:
19847644
11.

AKT alters genome-wide estrogen receptor alpha binding and impacts estrogen signaling in breast cancer.

Bhat-Nakshatri P, Wang G, Appaiah H, Luktuke N, Carroll JS, Geistlinger TR, Brown M, Badve S, Liu Y, Nakshatri H.

Mol Cell Biol. 2008 Dec;28(24):7487-503. doi: 10.1128/MCB.00799-08. Epub 2008 Oct 6.

12.
13.

Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer.

Normanno N, Di Maio M, De Maio E, De Luca A, de Matteis A, Giordano A, Perrone F; NCI-Naple Breast Cancer Group.

Endocr Relat Cancer. 2005 Dec;12(4):721-47. Review.

14.

Phosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer.

Yamashita H, Nishio M, Kobayashi S, Ando Y, Sugiura H, Zhang Z, Hamaguchi M, Mita K, Fujii Y, Iwase H.

Breast Cancer Res. 2005;7(5):R753-64. Epub 2005 Jul 27.

15.

A hidden Markov model to identify combinatorial epigenetic regulation patterns for estrogen receptor α target genes.

Bonneville R, Jin VX.

Bioinformatics. 2013 Jan 1;29(1):22-8. doi: 10.1093/bioinformatics/bts639. Epub 2012 Oct 26.

16.

Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor.

Vilquin P, Villedieu M, Grisard E, Ben Larbi S, Ghayad SE, Heudel PE, Bachelot T, Corbo L, Treilleux I, Vendrell JA, Cohen PA.

Int J Cancer. 2013 Oct 1;133(7):1589-602. doi: 10.1002/ijc.28182. Epub 2013 May 2.

PMID:
23553037
17.

Alteration of Y-box binding protein-1 expression modifies the response to endocrine therapy in estrogen receptor-positive breast cancer.

Ito T, Kamijo S, Izumi H, Kohno K, Amano J, Ito K.

Breast Cancer Res Treat. 2012 May;133(1):145-59. doi: 10.1007/s10549-011-1731-8. Epub 2011 Aug 24.

PMID:
21863258
18.

Resistance to endocrine therapy: are breast cancer stem cells the culprits?

O'Brien CS, Howell SJ, Farnie G, Clarke RB.

J Mammary Gland Biol Neoplasia. 2009 Mar;14(1):45-54. doi: 10.1007/s10911-009-9115-y. Epub 2009 Feb 28. Review.

PMID:
19252972
19.

Transient over-expression of estrogen receptor-α in breast cancer cells promotes cell survival and estrogen-independent growth.

Tolhurst RS, Thomas RS, Kyle FJ, Patel H, Periyasamy M, Photiou A, Thiruchelvam PT, Lai CF, Al-Sabbagh M, Fisher RA, Barry S, Crnogorac-Jurcevic T, Martin LA, Dowsett M, Charles Coombes R, Kamalati T, Ali S, Buluwela L.

Breast Cancer Res Treat. 2011 Jul;128(2):357-68. doi: 10.1007/s10549-010-1122-6. Epub 2010 Aug 22.

PMID:
20730598
20.

Toll-like receptor 9 agonist inhibits ERalpha-mediated transactivation by activating NF-kappaB in breast cancer cell lines.

Qiu J, Wang X, Guo X, Zhao C, Wu X, Zhang Y.

Oncol Rep. 2009 Oct;22(4):935-41.

PMID:
19724876
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk